Goldman Sachs Group Inc Corvus Pharmaceuticals, Inc. Transaction History

Goldman Sachs Group Inc

$596 Billion
Q1 2025

A detailed history of Goldman Sachs Group Inc transactions in Corvus Pharmaceuticals, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 368,318 shares of CRVS stock, worth $1.54 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

368,318

Previous 868,318 57.58%

Holding current value

$1.54 Million

Previous $2.76 Million 57.59%

% of portfolio

0.0%

Previous 0.0%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 16, 2025	SELL	$3.18 - $6.03 $1.59 Million - $3.02 Million	-500,000 Reduced 57.58%	368,318 $1.17 Million
Q1 2025 May 09, 2025	BUY	$3.18 - $6.03 $902,394 - $1.71 Million	283,772 Added 48.55%	868,318 $2.76 Million
Q4 2024 Feb 11, 2025	BUY	$4.55 - $9.56 $948,333 - $1.99 Million	208,425 Added 55.41%	584,546 $3.04 Million
Q3 2024 Nov 14, 2024	BUY	$1.78 - $5.92 $669,495 - $2.23 Million	376,121 New	376,121 $1.99 Million
Q3 2023 May 14, 2024	BUY	$1.41 - $2.97 $69,546 - $146,492	49,324 New	49,324 $72,000
Q3 2023 Nov 14, 2023	SELL	$1.41 - $2.97 $63,431 - $133,611	-44,987 Reduced 47.7%	49,324 $72,000
Q2 2023 May 14, 2024	BUY	$1.0 - $3.86 $77,050 - $297,413	77,050 Added 446.38%	94,311 $215,000
Q2 2023 Aug 14, 2023	BUY	$1.0 - $3.86 $94,311 - $364,040	94,311 New	94,311 $215,000
Q3 2022 May 14, 2024	SELL	$0.71 - $1.17 $16,038 - $26,429	-22,589 Reduced 56.69%	17,261 $14,000
Q3 2022 Nov 10, 2022	SELL	$0.71 - $1.17 $16,038 - $26,429	-22,589 Reduced 56.69%	17,261 $0
Q2 2022 May 14, 2024	BUY	$0.87 - $2.03 $34,669 - $80,895	39,850 New	39,850 $39,000
Q2 2022 Aug 15, 2022	SELL	$0.87 - $2.03 $26,748 - $62,412	-30,745 Reduced 43.55%	39,850 $39,000
Q1 2022 May 16, 2022	SELL	$1.46 - $2.48 $51,406 - $87,320	-35,210 Reduced 33.28%	70,595 $116,000
Q4 2021 Feb 14, 2022	BUY	$2.34 - $5.31 $189,181 - $429,297	80,847 Added 323.93%	105,805 $255,000
Q3 2021 Nov 10, 2021	BUY	$1.89 - $8.53 $47,170 - $212,891	24,958 New	24,958 $121,000

Others Institutions Holding CRVS

# of Institutions

105

Shares Held

36.7M

Call Options Held

1.37M

Put Options Held

338K

View Full List

About Corvus Pharmaceuticals, Inc.

Ticker CRVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,553,500
Market Cap $195M
Description
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...

More about CRVS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account

Goldman Sachs Group Inc Corvus Pharmaceuticals, Inc. Transaction History